Save time and get answers to complex questions with AI chat
The expiration date of the key patent for guselkumab?How does iron rich food intake impact lipitor's efficacy?Dabrafenib mesylate when the patent is expiring in india?What excipients are combined with ruxolitinib in apotex's medication?Bortezomib market france?
See the DrugPatentWatch profile for sapropterin
Mechanism of Action Sapropterin, also known as BH4 (tetrahydrobiopterin), is a non-hydroxylating aromatic amino acid hydroxylase cofactor [1]. It plays a crucial role in the metabolism of phenylalanine (Phe), an essential amino acid, in the body. In the absence of functional tetrahydrobiopterin (BH4), the enzyme phenylalanine hydroxylase (PAH) is impaired, leading to phenylketonuria (PKU), a genetic disorder characterized by high levels of phenylalanine in the blood. BH4 Supplementation In PKU patients with a moderate PAH deficiency, sapropterin supplementation has been shown to significantly increase phenylalanine oxidation and decrease plasma phenylalanine levels [2]. Sapropterin works by rescuing the impaired PAH enzyme, restoring its activity and allowing for normal phenylalanine metabolism. Comparison with BH4-Mimetics Other drugs, such as pegvaliase (Palynziq), have been developed as BH4-mimetics, which can increase PAH activity in PKU patients. However, these drugs have distinct mechanisms of action and may have different efficacy profiles compared to sapropterin [3]. Patent Considerations Sapropterin was first approved in 2007 under the brand name Kuvan, its patent for which has since expired [4]. This has led to the development of generic versions of the drug. Clinical Data Clinical trials have demonstrated the safety and efficacy of sapropterin in reducing plasma phenylalanine levels in PKU patients. However, individual response to the treatment may vary, and ongoing monitoring of phenylalanine levels is necessary to ensure optimal management of the condition [5]. Patient Considerations Sapropterin is an essential component of PKU management, particularly for patients with moderate PAH deficiency. However, it does not replace a strict PKU diet; patients should continue to adhere to a well-balanced, phenylalanine-restricted diet to manage their condition effectively. Sources: [1] https://www.drugpatentwatch.com/drug/kuvan [2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4441132/ [3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711413/ [4] https://www.drugpatentwatch.com/patent/17444278 [5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741248/
Other Questions About Sapropterin :